Another phase II trial showed that in patients with advanced HCC who had been previously treated with a multi-target kinase inhibitor sorafenib for HCC, PD-1 inhibitors pembrolizumab suggested an ORR rate of 17% and 77% of patients demonstrated sustained response for more than 9 months (Zhu et al., 2018). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.